Literature DB >> 9824612

The significance of haemochromatosis gene mutations in the general population: implications for screening.

M J Burt1, P M George, J D Upton, J A Collett, C M Frampton, T M Chapman, T A Walmsley, B A Chapman.   

Abstract

BACKGROUND: Haemochromatosis is associated with mutations in the HFE gene but the significance of these mutations in the general population is unknown. AIMS: To determine the frequency of HFE gene mutations in the general population, their effect on serum iron indexes, and their role in screening for haemochromatosis.
METHODS: Deoxyribonucleic acid (DNA) from 1064 randomly selected subjects was analysed for the C282Y and H63D mutations in the HFE gene. Serum iron, transferrin saturation, and ferritin were measured and individuals with increased iron indexes were investigated to confirm or exclude a clinical diagnosis of haemochromatosis.
RESULTS: Mutations were identified in 409 individuals (38.4%) with heterozygote (carrier) frequencies of 13.2% and 24.3% for the C282Y and H63D mutations respectively. Heterozygosity for either mutation significantly increased serum iron and transferrin saturation but despite a similar trend for ferritin, this was only significant for C282Y homozygotes. Five individuals (0.47%) were homozygous for the C282Y mutation, three of whom had haemochromatosis confirmed by liver biopsy (0.28%). The other two C282Y homozygotes would not have been detected by phenotypic screening alone.
CONCLUSIONS: HFE mutations are present in 38.4% of the population, affect serum iron indexes, and are important determinants of iron status. The population frequency of genetically defined haemochromatosis (C282Y homozygosity) is approximately one in 200 and is higher than the prevalence of clinically apparent haemochromatosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824612      PMCID: PMC1727339          DOI: 10.1136/gut.43.6.830

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  48 in total

1.  Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C.

Authors:  J K Olynyk; K R Reddy; A M Di Bisceglie; L J Jeffers; T I Parker; J L Radick; E R Schiff; B R Bacon
Journal:  Gastroenterology       Date:  1995-04       Impact factor: 22.682

2.  Expression of hemochromatosis in homozygous subjects. Implications for early diagnosis and prevention.

Authors:  L W Powell; K M Summers; P G Board; E Axelsen; S Webb; J W Halliday
Journal:  Gastroenterology       Date:  1990-06       Impact factor: 22.682

3.  Cost-effectiveness of screening for hereditary hemochromatosis.

Authors:  P D Phatak; G Guzman; J E Woll; A Robeson; C E Phelps
Journal:  Arch Intern Med       Date:  1994-04-11

Review 4.  Screening for hemochromatosis.

Authors:  C Q Edwards; J P Kushner
Journal:  N Engl J Med       Date:  1993-06-03       Impact factor: 91.245

5.  Long-term survival analysis in hereditary hemochromatosis.

Authors:  P C Adams; M Speechley; A E Kertesz
Journal:  Gastroenterology       Date:  1991-08       Impact factor: 22.682

6.  Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients.

Authors:  V Balan; W Baldus; V Fairbanks; V Michels; M Burritt; G Klee
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

7.  Investigation of subjects with abnormal iron studies: role of the hepatic iron index.

Authors:  B A Chapman; D M Horton; M J Burt; K R Romeril; T A Walmsley; S J Grant; P George
Journal:  N Z Med J       Date:  1994-12-14

8.  High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men.

Authors:  J T Salonen; K Nyyssönen; H Korpela; J Tuomilehto; R Seppänen; R Salonen
Journal:  Circulation       Date:  1992-09       Impact factor: 29.690

9.  Prevalence of abnormal iron studies in heterozygotes for hereditary hemochromatosis: an analysis of 255 heterozygotes.

Authors:  P C Adams
Journal:  Am J Hematol       Date:  1994-02       Impact factor: 10.047

10.  Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis.

Authors:  S Fargion; C Mandelli; A Piperno; B Cesana; A L Fracanzani; M Fraquelli; P A Bianchi; G Fiorelli; D Conte
Journal:  Hepatology       Date:  1992-04       Impact factor: 17.425

View more
  33 in total

1.  Population screening for haemochromatosis.

Authors:  P C Adams
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

2.  Variable phenotypic presentation of iron overload in H63D homozygotes: are genetic modifiers the cause?

Authors:  P Aguilar-Martinez; M Bismuth; M C Picot; C Thelcide; G P Pageaux; F Blanc; P Blanc; J F Schved; D Larrey
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

3.  The origin and spread of the HFE-C282Y haemochromatosis mutation.

Authors:  S Distante; K J H Robson; J Graham-Campbell; A Arnaiz-Villena; P Brissot; Mark Worwood
Journal:  Hum Genet       Date:  2004-09       Impact factor: 4.132

Review 4.  A diagnostic approach to hemochromatosis.

Authors:  Anthony S Tavill; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2006-08       Impact factor: 3.522

5.  Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk.

Authors:  Lynnette R Ferguson; Claudia Huebner; Ivonne Petermann; Richard B Gearry; Murray L Barclay; Pieter Demmers; Alan McCulloch; Dug Yeo Han
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

Review 6.  Is genetic screening for hemochromatosis worthwhile?

Authors:  Omer T Njajou; Behrooz Z Alizadeh; Cornelia M van Duijn
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

7.  Tumor necrosis factor receptor superfamily, member 1B haplotypes increase or decrease the risk of inflammatory bowel diseases in a New Zealand caucasian population.

Authors:  Lynnette R Ferguson; Dug Yeo Han; Claudia Huebner; Ivonne Petermann; Murray L Barclay; Richard B Gearry; Alan McCulloch; Pieter S Demmers
Journal:  Gastroenterol Res Pract       Date:  2009-05-03       Impact factor: 2.260

8.  HFE gene mutations increase the risk of coronary heart disease in women.

Authors:  M Carolina Pardo Silva; Omer T Njajou; Behrooz Z Alizadeh; Albert Hofman; Jacqueline C M Witteman; Cornelia M van Duijn; A Cecile J W Janssens
Journal:  Eur J Epidemiol       Date:  2010-07-18       Impact factor: 8.082

9.  Mutations in the hereditary haemochromatosis gene HFE in professional endurance athletes.

Authors:  J L Chicharro; J Hoyos; F Gómez-Gallego; J G Villa; F Bandrés; P Celaya; F Jiménez; J M Alonso; A Córdova; A Lucia
Journal:  Br J Sports Med       Date:  2004-08       Impact factor: 13.800

10.  Nucleotide-binding oligomerization domain containing 1 (NOD1) haplotypes and single nucleotide polymorphisms modify susceptibility to inflammatory bowel diseases in a New Zealand caucasian population: a case-control study.

Authors:  Claudia Huebner; Lynnette R Ferguson; Dug Yeo Han; Martin Philpott; Murray L Barclay; Richard B Gearry; Alan McCulloch; Pieter S Demmers; Brian L Browning
Journal:  BMC Res Notes       Date:  2009-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.